The round was led by RiverVest Venture Partners and Mass General Brigham Ventures along with Digitalis Ventures, Casdin Capital, KdT Ventures, Bold Capital Partners and Alexandria Venture Investments. Funds will be used for initial company development leading to establishment of a full-service laboratory providing off-target gene-editing analysis for use in drug development, clinical trials and ultimately patient evaluation prior to therapy.

SeQure dx, is applying state of the art genomics technologies for CRISPR gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Their technologies provide the foundation needed to ensure that life-saving gene therapies will be both safe and effective.